MedPath

Suven Life Sciences' Ropanicant Shows Positive Phase 2a Results for Major Depressive Disorder

• Suven Life Sciences announced positive results from its Phase 2a proof-of-concept study of Ropanicant (SUVN-911) in patients with moderate to severe Major Depressive Disorder (MDD). • Ropanicant, an α4β2 nicotinic acetylcholine receptor (nAChR) antagonist, demonstrated promising safety and efficacy outcomes in the open-label Phase 2a study. • Suven plans to advance Ropanicant into a double-blind, placebo-controlled Phase 2b clinical study in MDD patients, anticipated to start in early 2025. • The company will present these findings at the upcoming Neuroscience 2024 conference, highlighting its portfolio of new chemical entities.

Suven Life Sciences Ltd. has announced positive results from its Phase 2a proof-of-concept study evaluating Ropanicant (SUVN-911) for the treatment of moderate to severe Major Depressive Disorder (MDD). The company plans to present these findings at the Neuroscience 2024 conference in Chicago, Illinois.
Ropanicant (SUVN-911) is a selective α4β2 nicotinic acetylcholine receptor (nAChR) antagonist. The Phase 2a study evaluated the safety and efficacy of Ropanicant in participants with moderate to severe MDD. While specific data from the Phase 2a trial were not detailed in the announcement, the company stated the results were positive, paving the way for further clinical development.

Planned Phase 2b Trial

Based on the Phase 2a results, Suven intends to initiate a double-blind, placebo-controlled Phase 2b clinical study of Ropanicant in MDD patients. The Phase 2b trial is anticipated to begin in early 2025. This study will provide more definitive data on the efficacy and safety of Ropanicant compared to placebo.

Suven's Neuroscience 2024 Presentations

In addition to Ropanicant, Suven Life Sciences will present data on other clinical and preclinical assets at Neuroscience 2024, including:
  • Samelisant (SUVN-G3031): Phase 2 proof-of-concept study results in patients with narcolepsy.
  • Masupirdine (SUVN-502): Rationale and study design for the Phase 3 clinical development program for agitation in patients with dementia of Alzheimer’s type.
  • SUVN-2206043: A dual 5-HT1A and 5-HT2A receptor ligand showing antipsychotic and antidepressant-like effects in animal models.
  • SUVN-L3307032: A positive allosteric modulator (PAM) at the muscarinic M4 receptor for the treatment of psychotic symptoms.

Suven's Clinical Pipeline

Suven currently has seven clinical-stage assets across various therapeutic areas. These include Masupirdine (SUVN-502) for agitation in Alzheimer's disease (Phase 3), Samelisant (SUVN-G3031) for excessive daytime sleepiness in narcolepsy (Phase 2 completed, Phase 3 planning), Ropanicant (SUVN-911) for MDD (Phase 2a completed, Phase 2b planning), Usmarapride (SUVN-D4010) for cognitive disorders (Phase 2 planning), and SUVN-I6107 for cognitive disorders (Phase 1 initiated), along with two other compounds in early clinical development. The company also has six projects in the research pipeline.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Bionxt Solutions to Evaluate Sublingual Cladribine Formulation for Multiple Sclerosis in Clinical Trial

Bionxt Solutions plans to initiate a clinical trial in the second half of 2025 to assess its sublingual cladribine formulation, BNT23001, for treating multiple sclerosis.
The trial aims to compare the safety, efficacy, and bioavailability of BNT23001 with the oral formulation Mavenclad in patients with MS.

Bionomics' BNC210 Shows Positive Phase 2 Results in PTSD Patients, Phase 3 Planned

Bionomics' BNC210 demonstrated statistically significant improvement in PTSD symptom severity compared to placebo at Week 12, with benefits observed as early as Week 4.
The Phase 2 ATTUNE study also revealed clinically meaningful improvements in depressive symptoms and sleep quality among patients treated with BNC210.

SynAct Pharma's Resomelagon Receives EU Trial Approval for Phase 2b Rheumatoid Arthritis Study

SynAct Pharma received EU approval for its Phase 2b ADVANCE study of resomelagon (AP1189) in newly diagnosed severe rheumatoid arthritis (RA) patients.
The ADVANCE study will evaluate three doses of resomelagon versus placebo, in combination with methotrexate, as a first-line RA treatment.

Adaptimmune's Lete-cel Shows Promise in Sarcoma, Nearing Potential Approval

Adaptimmune's lete-cel met its primary endpoint in a Phase II trial for advanced or metastatic synovial sarcoma and myxoid/round cell liposarcoma (MRCLS).
The IGNYTE-ESO trial data showed a 42% response rate in patients treated with lete-cel, with median response durations of 18.3 months for synovial sarcoma and 12.2 months for MRCLS.

Revumenib Shows Promise in Phase 2 Trial for Relapsed/Refractory AML

Syndax Pharmaceuticals' revumenib demonstrated a 23% complete remission rate in patients with relapsed or refractory mutant NPM1 acute myeloid leukemia (AML).
The AUGMENT-101 trial also showed a 47% overall response rate in heavily pre-treated AML patients, including those who had prior venetoclax exposure.

Mirdametinib Shows Promise in Neurofibromatosis Type 1-Associated Plexiform Neurofibromas

Mirdametinib demonstrates significant objective response rates and a manageable safety profile in both adult and pediatric patients with NF1-PN.
The ReNeu trial highlights deep and durable tumor volume reductions, alongside early and sustained improvements in pain and quality of life.

Antengene to Present Selinexor Data from Phase III Multiple Myeloma and Phase I/II Lymphoma Studies at ASH 2024

Antengene will present Phase III results of weekly selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in Chinese patients with relapsed/refractory multiple myeloma.
Preliminary results from a Phase I/II study of selinexor combined with tislelizumab in relapsed/refractory extranodal NK/T-cell lymphoma will also be presented.

MSD's Clesrovimab Shows Promise in RSV Prevention, Eyes 2025 Launch

MSD's clesrovimab demonstrated a 60% reduction in RSV-associated medically attended lower respiratory infections (MALRI) in infants in a Phase IIb/III trial.
The monoclonal antibody also reduced RSV-associated hospitalizations by 84.2% and LRTD hospitalizations by 90.9% over five months compared to placebo.

Innovent's Mazdutide Shows Superior Efficacy in Type 2 Diabetes and Obesity Trials

Mazdutide demonstrated superior blood sugar control and weight loss compared to dulaglutide in the Phase 3 DREAMS-2 trial for type 2 diabetes.
In the GLORY-1 trial, mazdutide led to significant weight reduction in overweight or obese patients, with over 50% achieving at least a 15% body weight reduction.

Reference News

[1]
Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant
indianpharmapost.com · Oct 5, 2024

Suven Life Sciences to present results from Phase-2a study of Ropanicant at Neuroscience 2024, planning Phase-2b study f...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy